Atyr Pharma Inc (ATYR) Stock Price, Quote & News

Company Profile

aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; and in Phase 1b/2a clinical trial to treat other interstitial lung diseases (ILDs), such as chronic hypersensitiv...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 731 8389

Fax: 858 731 8394

Website: atyrpharma.com

Address:

10240 Sorrento Valley Road, Suite 300, San Diego, United States

trader2sde Feb. 3 at 1:28 PM

$ATYR now expect evidently the reactions of HC WAINWRIGHT, CANTOR and others ...probably views with 2 outcomes as last time. but this is positive having a new meeting with the FDA. ( remember there is no drug for lung sarcoidosis).

0 · Reply

trader2sde Feb. 3 at 1:23 PM

$ATYR https://www.stocktitan.net/news/ATYR/a-tyr-pharma-announces-scheduling-of-fda-type-c-meeting-to-discuss-yx144up3xwvc.html

0 · Reply

trader2sde Feb. 3 at 1:20 PM

$ATYR

0 · Reply

A416 Feb. 3 at 1:18 PM

$ATYR Today we announced that we are scheduled to meet with the U.S. FDA in mid-April 2026 for a Type C meeting to review the results from the Phase 3 EFZO-FIT™ study and determine the path forward for #efzofitimod in #pulmonarysarcoidosis. Read more: http://bit.ly/4bEnIxr

0 · Reply

rio245 Feb. 3 at 1:12 PM

$ATYR

0 · Reply

NNTrader Feb. 3 at 7:35 AM

$ATYR any news why it's up?

1 · Reply

trader2sde Feb. 2 at 9:22 PM

$ATYR we stand in the $4 target range but still substantial.

1 · Reply

Cris0 Feb. 2 at 8:39 PM

$ATYR 5 soon

1 · Reply

cliffman1983 Feb. 2 at 8:11 PM

$ATYR Give me 1$$$ 💸

1 · Reply

WelshDragon75 Feb. 2 at 8:01 PM

$ATYR over the $1 let’s go!

0 · Reply

aTyr Pharma Announces Scheduling of FDA Type C Meeting to Discuss Efzofitimod Program in Pulmonary Sarcoidosis

Jan 30, 2026, 10:25 PM EST - 3 days ago

U.S. IPO Weekly Recap: Trio Of Sizable Listings Underwhelm To Close Out January

AGMB BOBS EIKN FPS LFTO LIFE OFRM

Jan 30, 2026, 12:21 AM EST - 4 days ago

Ethos Technologies: A Surprisingly Soft Debut

LIFE

Jan 29, 2026, 12:30 PM EST - 4 days ago

Insurance platform Ethos Technologies valued at $1.2 billion in Nasdaq debut

LIFE

Jan 28, 2026, 10:38 PM EST - 5 days ago

Ethos Announces Pricing of Initial Public Offering

LIFE

Jan 28, 2026, 9:05 PM EST - 5 days ago

Ethos Technologies prices US IPO at $19/share, Bloomberg News reports

LIFE

Jan 23, 2026, 10:45 PM EST - 10 days ago

U.S. IPO Weekly Recap: Equipment Rental Rises While Crypto Company Crashes In 2-IPO Week

BTGO CSIG EQPT LIFE PICS PPHC YSS

Jan 7, 2026, 8:01 AM EST - 27 days ago

Ethos and North American Collaborate to Offer Accumulation Indexed Universal Life Product

LIFE

Jan 2, 2026, 10:35 PM EST - 4 weeks ago

U.S. IPO Weekly Recap: Small Issuers And SPACs Join The Pipeline In Short Holiday Week

APC BTGO EQPT GRAY IBL KLK LIFE

Dec 18, 2025, 8:01 AM EST - 6 weeks ago

Ethos and Aflac Partner to Bring Supplemental Health Product Suite to Independent Distribution

LIFE

Dec 15, 2025, 2:45 PM EST - 7 weeks ago

Johnson Fistel Investigates Claims on Behalf of aTyr Pharma, Inc. (ATYR) Shareholders

Dec 8, 2025, 3:25 AM EST - 2 months ago

aTyr Pharma, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - ATYR

Dec 7, 2025, 9:02 AM EST - 2 months ago

ATYR DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma

Dec 6, 2025, 12:58 PM EST - 2 months ago

ATYR Lawsuit: Hagens Berman Urges aTyr Pharma Investors to Act by Dec. 8 Deadline in Suit Over Trial Failure

Dec 4, 2025, 10:56 AM EST - 2 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma

Dec 3, 2025, 4:21 PM EST - 2 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of December 8, 2025 in aTyr Lawsuit – ATYR

Dec 3, 2025, 9:22 AM EST - 2 months ago

ATYR INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma

Dec 1, 2025, 6:32 PM EST - 2 months ago

UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma

Nov 26, 2025, 11:34 AM EST - 2 months ago

The Short List — Top 10 Most Shorted Stocks Right Now

CMBM HIMS HTZ LCID NTLA REPL SOC

Nov 25, 2025, 4:08 PM EST - 2 months ago

aTyr Pharma (ATYR) Posts Wider-Than-Expected Loss as Investor Litigation Over Key Drug's Efficacy Moves Forward -- Hagens Berman

Nov 20, 2025, 8:45 AM EST - 2 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of December 8, 2025 in aTyr Pharma, Inc. Lawsuit - ATYR

Nov 18, 2025, 2:03 PM EST - 2 months ago

ATYR INVESTOR NOTICE: New aTyr Pharma, Inc. (ATYR) Securities Class Filed; Class Period Significantly Enlarged -- Hagens Berman

Nov 11, 2025, 9:23 AM EST - 3 months ago

aTyr Pharma, Inc. (ATYR) Failed Drug Trial Spurs Securities Lawsuit; Class Period Significantly Enlarged -- Hagens Berman

Nov 10, 2025, 8:00 AM EST - 3 months ago

aTyr Pharma to Present at Piper Sandler 37th Annual Healthcare Conference

Nov 6, 2025, 4:01 PM EST - 3 months ago

aTyr Pharma Announces Third Quarter 2025 Results and Provides Corporate Update

Nov 4, 2025, 11:49 AM EST - 3 months ago

ATYR INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ATyr Pharma

Oct 30, 2025, 11:33 AM EDT - 3 months ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma

Oct 30, 2025, 8:45 AM EDT - 3 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of December 8, 2025 in aTyr Lawsuit - ATYR

Oct 28, 2025, 9:34 AM EDT - 3 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma

Oct 23, 2025, 1:28 PM EDT - 3 months ago

ATYR INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma

Oct 22, 2025, 4:49 PM EDT - 3 months ago

aTyr Pharma, Inc.'s (ATYR) Failed Drug Trial Spurs Securities Lawsuit -- Hagens Berman

trader2sde Feb. 3 at 1:28 PM

0 · Reply

trader2sde Feb. 3 at 1:23 PM

$ATYR https://www.stocktitan.net/news/ATYR/a-tyr-pharma-announces-scheduling-of-fda-type-c-meeting-to-discuss-yx144up3xwvc.html

0 · Reply

trader2sde Feb. 3 at 1:20 PM

$ATYR

0 · Reply

A416 Feb. 3 at 1:18 PM

0 · Reply

rio245 Feb. 3 at 1:12 PM

$ATYR

0 · Reply

NNTrader Feb. 3 at 7:35 AM

$ATYR any news why it's up?

1 · Reply

trader2sde Feb. 2 at 9:22 PM

$ATYR we stand in the $4 target range but still substantial.

1 · Reply

Cris0 Feb. 2 at 8:39 PM

$ATYR 5 soon

1 · Reply

cliffman1983 Feb. 2 at 8:11 PM

$ATYR Give me 1$$$ 💸

1 · Reply

WelshDragon75 Feb. 2 at 8:01 PM

$ATYR over the $1 let’s go!

0 · Reply

amuriel Feb. 2 at 7:59 PM

$ATYR $$$$1.000000

0 · Reply

JustB4SnR1se Feb. 2 at 7:47 PM

$ATYR needs volume to break here.

0 · Reply

Tfizzle Feb. 2 at 6:56 PM

$ATYR

0 · Reply

trader2sde Feb. 2 at 6:56 PM

$ATYR

1 · Reply

BobbyBalentino Feb. 2 at 6:47 PM

$ATYR Insiders accumulating shares last month

1 · Reply

Boxcar66 Feb. 2 at 6:35 PM

$ATYR Follow the money

1 · Reply

WelshDragon75 Feb. 2 at 6:26 PM

$ATYR extremely bullish action here this past several days.

0 · Reply

idunnobro Feb. 2 at 6:20 PM

$ATYR i held this ticker for just about 2 years. Held thru the P3 failure, kept telling myself it's a loss either way, I'll see if there's a bounce off FDA news in 2026 and then sell either way, maybe recoup some loss. I finally got impatient last week and decided to close the position - you're welcome for the turnaround, everyone.

1 · Reply

Finwizard61 Feb. 2 at 6:17 PM

$ATYR Picked up 5,000 and hoping to another 5,000 too..

0 · Reply

enzomassimi Feb. 2 at 6:16 PM

$ATYR fly now

0 · Reply

JustB4SnR1se Feb. 2 at 6:16 PM

$ATYR

0 · Reply

OnlyBuyMoreShareSqueezes Feb. 2 at 6:11 PM

$ATYR we are close to closing back at 1 + push the ask higher and HOLD . Buy and hold with us

0 · Reply

Market Cap	86.50M
Revenue (ttm)	240,000.00
Net Income (ttm)	-64.02M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-26,675.00%
Debt to Equity Ratio	0.00

Volume	7,277,000
Avg Vol	2,329,676
Day's Range	N/A - N/A
Shares Out	97.99M
Stochastic %K	86%
Beta	0.60
Analysts	Sell
Price Target	$4.00